This morning, Concordia announced it would buy Covis Pharma SARL and Covis Injectables SARL for (U.S.) $1.2-billion in cash. The company said it would finance the pickup through a combination of term loans, bonds and equity.
“Covis’s strong commercial momentum will have an immediate and material impact on our top- and bottom-line financial results,” said CEO Mark Thompson. “In the longer term, this transaction creates greater scale and diversification for Concordia, which should support the continued execution of our aggressive growth plans.”
Walewicz says this acquisition adds “substantially” to Concordia’s top and bottom line. Although he notes that all the operating metrics are not yet available, he estimates the deal was done at about 6x pro forma revenues. He points out that Covis’s gross margins are in the 90% range and the company adds no new headcount and has limited operating expenses.
The analyst says this deal will effectively double the size of Concordia.
“CXR expects its existing business to deliver US$40-43 million in revenue in the fourth quarter and the the Covis Assets to deliver approx. US$47-52 million in revenues in the same period,” he notes.
In a research update to clients this morning, Walewicz maintained his “Buy” rating on Concordia Healthcare and placed his target price, which was set at $48.00, under review.
Shares of Concordia Healthcare today closed up 25.2% to $80.34.
Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]
Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]
The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]
Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]
He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]
Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]